Objective： To analyze the clinical characteristics and patterns of allergic shock induced by ceftriaxone sodium, and provide a basis for ensuring the safety of clinical medication. Methods: A search was conducted on the literature on ceftriaxone sodium induced anaphylactic shock published domestically and internationally from 2011 to 2024. Case reports of ceftriaxone sodium induced anaphylactic shock were selected and retrospectively analyzed. Results: A total of 46 cases of allergic shock caused by ceftriaxone sodium were retrieved. Among these cases, 73.9% experienced allergic shock during the first use of the drug, 26.1% experienced allergic shock after continuous use, and 4 cases experienced allergic shock during skin testing; The overall mortality rate reached 10.8%. Conclusion: The clinical application of ceftriaxone sodium requires strict adherence to diagnostic and treatment standards, individualized medication plans tailored to individual patient differences, monitoring of individual vital signs, and establishment of emergency response plans for acute allergic reactions to ensure patient medication safety.